US-based biotechnology company Flex Pharma is planning to conduct Phase II clinical programmes to evaluate FLX-787 for treatment of severe neurological diseases of amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS) and peripheral neuropathies such as Charcot-Marie Tooth (CMT).

FLX-787 is a chemically synthesised, single molecule, transient receptor potential (TRP), ion channel activator that has been formulated as an oral tablet.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Under the clinical programmes, the company will conduct proof-of-concept Phase II studies of FLX-787 and two separate exploratory Phase II studies initiated by Flex Pharma, including MS and ALS patients in Australia last year.

"Our approach has a broad range of applications that we believe will ultimately benefit the millions of people that suffer from frequent painful muscle cramps."

The studies will be designed as randomised, controlled, blinded, cross-over trials intended to test the safety and efficacy of FLX-787 in patients who suffer from symptoms such as cramps and spasticity triggered by the disease.

Flex Pharma Scientific co-founder, board member, scientific advisory board co-chair and Nobel laureate Dr Rod MacKinnon said: “We believe that topical Chemical Neuro Stimulation, the process whereby small molecules activate TRP ion channels on sensory nerves in the oral mucosa, triggers a reflex response to inhibit the hyperexcitable motor neurons in the spinal cord and reduce muscle cramps.

“Our approach has a broad range of applications that we believe will ultimately benefit the millions of people that suffer from frequent painful muscle cramps.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company is expected to release results from the exploratory MS study by the end of this year.